DOCSLIB.ORG

Blueprint Genetics Ectodermal Dysplasia Panel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Blueprint Genetics Ectodermal Dysplasia Panel Ectodermal Dysplasia Panel Test code: DE0401 Is a 25 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of ectodermal dysplasia (hidrotic or hypohidrotic) or Ellis-van Creveld syndrome. About Ectodermal Dysplasia Ectodermal Dysplasia (ED) is a group of closely related conditions of which more than 150 different syndromes have been identified. EDs affects the development or function of teeth, hair, nails and sweat glands. ED may present as isolated or as part of a syndromic disease and is commonly subtyped according to sweating ability. The clinical features of the X-linked and autosomal forms of hypohidrotic ectodermal dysplasia (HED) can be indistinguishable and many of the involved genes may lead to phenotypically distinct outcomes depending on number of defective alleles. The most common EDs are hypohidrotic ED and hydrotic ED. X-linked hypohidrotic ectodermal dysplasia (HED) is caused by EDA mutations and explain 75%-95% of familial HED and 50% of sporadic cases. HED is characterized by three cardinal features: hypotrichosis (sparse, slow-growing hair and sparse/missing eyebrows), reduced sweating and hypodontia (absence or small teeth). Reduced sweating poses risk for episodes of hyperthermia. Female carriers may have some degree of hypodontia and mild hypotrichosis. Isolated dental phenotypes have also been described. Mutations in WNT10A have been reported in up to 9% of individuals with HED and in 25% of individuals with HED who do not have defective EDA. Approximately 50% of individuals with heterozygous WNT10A mutation have HED and the most consistent clinical feature is severe oligodontia of permanent teeth. Mutations in EDAR explain 7% of HED and are associated with both autosomal dominant and recessive ED. This panel provide differential diagnostic power as it covers many syndromes that may present with ED. Several syndromes characterized by ED and hearing loss are associated with GJB2 mutations including KID syndrome, Vohwinkel syndrome, Bart-Pumphrey syndrome. Hidrotic ED type 2 is caused by autosomal dominant GJB6 mutations and characterized by hypotrichosis, dysplastic nails and palmoplantar hyperkeratosis. Unlike other ectodermal dysplasias, sweating and tooth development are normal. Recessive EVC and EVC2 mutations cause Ellis-van Creveld syndrome characterized by ED, dwarfism, polydactyly and heart defects, however, dominant mutations in the same genes cause the less severe Weyers acrofacial dysostosis. Expression of DSP- related ED is variable including woolly hair, alopecia, hyperkeratotic plaques, failure to thrive, dilated and arrhythmogenic right ventricular cardiomyopathy. The most severe presentation is lethal acantholytic epidermolysis bullosa. The prevalence of HED is estimated to be 1:5,000-10,000 newborns while that of Ellis-van Creveld syndrome is 1:60,000 – 200,000. Availability 4 weeks Gene Set Description Genes in the Ectodermal Dysplasia Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD BCS1L Bjornstad syndrome, GRACILE syndrome, Leigh syndrome, AR 42 37 Mitochondrial complex III deficiency, nuclear type 1 CDH3 Hypotrichosis, congenital, with juvenile macular dystrophy, AR 7 30 Ectodermal dysplasia, ectrodactyly, and macular dystrophy syndrome DSP Cardiomyopathy, dilated, with wooly hair, keratoderma, and tooth AD/AR 177 296 agenesis, Arrhythmogenic right ventricular dysplasia, familial, Cardiomyopathy, dilated, with wooly hair and keratoderma, Keratosis palmoplantaris striata II, Epidermolysis bullosa, lethal acantholytic EDA Ectodermal dysplasia, hypohidrotic, Tooth agenesis, selective XL 115 326 https://blueprintgenetics.com/ EDAR Ectodermal dysplasia, anhidrotic, Hair morphology AD/AR 38 61 EDARADD Ectodermal dysplasia, anhidrotic, autosomal recessive, Ectodermal AD/AR 8 10 dysplasia, anhidrotic, autosomal dominant, Ectodermal dysplasia, hypohidrotic, autosomal dominant, Ectodermal dysplasia, hypohidrotic, autosomal recessive ERCC2 Xeroderma pigmentosum, Trichothiodystrophy, photosensitive, AR 26 98 Cerebrooculofacioskeletal syndrome 2 EVC Weyers acrofacial dysostosis, Ellis-van Creveld syndrome AD/AR 58 83 EVC2 Ellis-van Creveld syndrome, Weyers acrodental dysostosis AD/AR 78 75 GJB2 Deafness, Bart-Pumphrey syndrome, Keratoderma, palmoplantar, with AD/AR/Digenic 133 405 deafness, Vohwinkel syndrome, Hystrix-like ichthyosis with deafness, Keratitis-icthyosis-deafness syndrome GJB6 Deafness, Deafness, autosomal dominant 3B, Ectodermal dysplasia, AD/AR 10 33 hidrotic (Clouston syndrome) HOXC13 Ectodermal dysplasia 9 AR 3 10 HR Hypotrichosis 4, Atrichia with papular lesions, Alopecia universalis AD/AR 15 52 congenita IFT122* Sensenbrenner syndrome, Cranioectodermal dysplasia (Levin- AR 13 23 Sensenbrenner) type 1, Cranioectodermal dysplasia (Levin- Sensenbrenner) type 2 JUP Arrhythmogenic right ventricular dysplasia, Naxos disease AD/AR 8 46 LRP6 Tooth agenesis, selective, 7 AD 19 37 MPLKIP Trichothiodystrophy 4, nonphotosensitive AR 8 19 PAX9 Tooth agenesis, selective, 3 AD 19 57 PORCN Focal dermal hypoplasia XL 16 121 PRKD1 Congenital heart defects and ectodermal dysplasia AD 2 7 PVRL4 Ectodermal dysplasia-syndactyly syndrome 1 AR 6 10 RMRP Cartilage-hair hypoplasia, Metaphyseal dysplasia without AR 87 123 hypotrichosis, Anauxetic dysplasia TP63 Rapp-Hodgkin syndrome, Orofacial cleft, ADULT syndrome, AD 59 122 Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome, Ankyloblepharon-ectodermal defects-cleft lip/palate, Split-hand/foot malformation, Limb-mammary syndrome WDR35 Cranioectodermal dysplasia (Levin-Sensenbrenner) type 1, AR 28 31 Cranioectodermal dysplasia (Levin-Sensenbrenner) type 2, Short rib- polydactyly syndrome type 5 WNT10A Odontoonychodermal dysplasia, Tooth agenesis, selective, Schopf- AD/AR 23 81 Schulz-Passarge syndrome *Some regions of the gene are duplicated in the genome. Read more. # The gene has suboptimal coverage (means <90% of the gene’s target nucleotides are covered at >20x with mapping quality https://blueprintgenetics.com/ score (MQ>20) reads), and/or the gene has exons listed under Test limitations section that are not included in the panel as they are not sufficiently covered with high quality sequence reads. The sensitivity to detect variants may be limited in genes marked with an asterisk (*) or number sign (#). Due to possible limitations these genes may not be available as single gene tests. Gene refers to the HGNC approved gene symbol; Inheritance refers to inheritance patterns such as autosomal dominant (AD), autosomal recessive (AR), mitochondrial (mi), X-linked (XL), X-linked dominant (XLD) and X-linked recessive (XLR); ClinVar refers to the number of variants in the gene classified as pathogenic or likely pathogenic in this database (ClinVar); HGMD refers to the number of variants with possible disease association in the gene listed in Human Gene Mutation Database (HGMD). The list of associated, gene specific phenotypes are generated from CGD or Mitomap databases. Non-coding disease causing variants covered by the panel Gene Genomic location HG19 HGVS RefSeq RS-number BCS1L Chr2:219524871 c.-147A>G NM_004328.4 BCS1L Chr2:219525123 c.-50+155T>A NM_004328.4 rs386833855 EDA ChrX:69249341 c.707-13T>C/G NM_001399.4 EDA ChrX:69249341 c.707-13T>C NM_001399.4 EDA ChrX:69249341 c.707-13T>G NM_001399.4 EVC Chr4:5749725 c.940-150T>G NM_153717.2 GJB2 Chr13:20763744 c.-22-2A>C NM_004004.5 rs201895089 GJB2 Chr13:20766920 c.-23+2T>A NM_004004.5 GJB2 Chr13:20766921 c.-23+1G>A NM_004004.5 rs80338940 GJB2 Chr13:20766922 c.-23G>T NM_004004.5 rs786204734 GJB2 Chr13:20767158 c.-259C>T NM_004004.5 GJB2 Chr13:20767159 c.-260C>T NM_004004.5 HR Chr8:21988118 c.-218A>G NM_005144.4 rs267606869 HR Chr8:21988149 c.-249C>G NM_005144.4 rs267606868 HR Chr8:21988215 c.-315C>T NM_005144.4 rs267606867 HR Chr8:21988220 c.-320T>C NM_005144.4 rs387906382 IFT122 Chr3:129207087 c.2005-13T>A NM_052985.3 PAX9 Chr14:37130036 c.-393-866G>A NM_006194.3 PORCN ChrX:48370668 c.374-46T>A NM_203475.1 PORCN ChrX:48370699 c.374-15G>A NM_203475.1 RMRP Chr9:35658026 NR_003051.3 rs781730798 RMRP Chr9:35658026 NR_003051.3 https://blueprintgenetics.com/ RMRP Chr9:35658026 NR_003051.3 RMRP Chr9:35658026 NR_003051.3 RMRP Chr9:35658027 NR_003051.3 RMRP Chr9:35658027 NR_003051.3 RMRP Chr9:35658027 NR_003051.3 RMRP Chr9:35658027 NR_003051.3 rs727502775 RMRP Chr9:35658027 NR_003051.3 RMRP Chr9:35658028 NR_003051.3 RMRP Chr9:35658028 NR_003051.3 RMRP Chr9:35658029 NR_003051.3 RMRP Chr9:35658029 NR_003051.3 RMRP Chr9:35658032 NR_003051.3 WDR35 Chr2:20151929 c.1434-684G>T NM_001006657.1 WDR35 Chr2:20182313 c.143-18T>A NM_001006657.1 Test Strengths Our panel assay enables the detection of common deletions in GJB6 such as ((~309 kb del (GJB6-D13S1830) and ~232 kb del (GJB6-D13S1854)). The strengths of this test include: CAP accredited laboratory CLIA-certified personnel performing clinical testing in a CLIA-certified laboratory Powerful sequencing technologies, advanced target enrichment methods and precision bioinformatics pipelines ensure superior analytical performance Careful construction of clinically effective and scientifically justified gene panels Some of the panels include the whole mitochondrial genome (please see the Panel Content section) Our Nucleus online portal providing transparent and easy access to quality and performance data at the patient level Our publicly available analytic validation demonstrating complete details of test performance ~2,000 non-coding disease causing variants
Load more

Recommended publications
  • Ectodermal Dysplasias: a New Clinical-Genetic Classification
    J Med Genet 2001;38:579–585 579 Ectodermal dysplasias: a new clinical-genetic J Med Genet: first published as 10.1136/jmg.38.9.579 on 1 September 2001. Downloaded from classification Manuela Priolo, Carmelo Laganà Abstract many case reports and personal communica- The ectodermal dysplasias (EDs) are a tions in their listing of EDs, as well as large and complex nosological group of conditions traditionally classified under other diseases, first described by Thurnam in headings, for example dyskeratosis congenita11 1848. In the last 10 years more than 170 and keratitis-ichthyosis-deafness (KID) syn- diVerent pathological clinical conditions drome12 (poikiloderma and immune defect have been recognised and defined as EDs, diseases and erythrokeratodermas, respec- all sharing in common anomalies of the tively). Further, they did not appear to hair, teeth, nails, and sweat glands. Many consider variability of expression and may are associated with anomalies in other have reported, as distinct diseases, conditions organs and systems and, in some condi- that reflect variable expression of the same tions, with mental retardation. pathological entity. Moreover, they included The anomalies aVecting the epidermis pathological conditions which, in our opinion, and epidermal appendages are extremely do not strictly fulfil the diagnostic criteria for variable and clinical overlap is present EDs, such as conditions with secondary among the majority of EDs. Most EDs are involvement of epidermal derivatives rather defined by particular clinical signs (for than a primary defect. We abandoned the 1-2- example, eyelid adhesion in AEC syn- 3-4 designation of EDs, because we believe drome, ectrodactyly in EEC).
    [Show full text]
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
    [Show full text]
  • EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies
    Focusing on Personalised Medicine EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies Extended carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Genomics For Life offers a comprehensive Extended Carrier Screening test, providing prospective parents with the information they require when planning their pregnancy. Extended Carrier Screening has been shown to detect carriers who would not have been considered candidates for traditional risk- based screening. With a simple mouth swab collection, we are able to test for over 419 genes associated with inherited diseases, including Fragile X Syndrome, Cystic Fibrosis and Spinal Muscular Atrophy. The assay has been developed in conjunction with clinical molecular geneticists, and includes genes listed in the NIH Genetic Test Registry. For a list of genes and disorders covered, please see the reverse of this brochure. If your gene of interest is not covered on our Extended Carrier Screening panel, please contact our friendly team to assist you in finding a gene test panel that suits your needs. Why have Extended Carrier Screening? Extended Carrier Screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or to use donor gametes.
    [Show full text]
  • Disease Reference Book
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • Goltz Syndrome Nsu-Com / Larkin Community Hospital Presenters: Ann R Eed, Do, Hyunhee Park, Do, Julie Frederickson , Do
    GOLTZ SYNDROME NSU-COM / LARKIN COMMUNITY HOSPITAL PRESENTERS: ANN R EED, DO, HYUNHEE PARK, DO, JULIE FREDERICKSON , DO. PROGRAM DIRECTOR: STANLEY SKOPIT, DO, MSE, FAOCD Case presentation 17 year old female with established diagnosis of Goltz syndrome presented to our office Jan. 2011 with c/o “Dry skin and itchy scalp” PE: Syndromic facies w/ aniridia, microphthalmia, short stature, sparse hair, hypodontia, syndactyly, blaschko linear hyper and hypopigmentation, perioral papillomas, scaly scalp and xerotic skin Dx: Xerosis Cutis , Seborrhea and alopecia in patient with Goltz Tx: Ketoconazole 2% shampoo MWF alt with T/Sal Lidex solution BID x 2 weeks to scalp Cerave/Cetaphil to body Biotin 2500 mcg daily Bx’s: 3/8/11 Shave biopsy (R labial commissure) - Verruca with candidiasis 3/22/11 Shave biopsy (L labial commissure) - Impetiginized Verruca with candidiasis Ketoconazole 2% cream BID given for topical treatment Goltz Syndrome Overview Focal Dermal Hypoplasia or Goltz-Gorlin syndrome Rare genodermatosis Multiple abnormalities of mesodermal and ectodermal tissues First described by Dr. Goltz in 1962 Approximately 300 reported cases worldwide Inheritance X-linked dominant 90% female Lethal in males with non-mosaic hemizygous mutations 10% affected individuals: males with genomic or functional mosaicism 95% of cases are sporadic Gene locus Xp11.23 Mutation in PORCN gene lack of Wnt signaling Variability in clinical severity (lyonization) Goltz Syndrome Cutaneous Findings Wu M-C et al. / Dermatologica Sinica 29 (2011) 59-62 Wang
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Xeroderma Pigmentosum
    Xeroderma pigmentosum Description Xeroderma pigmentosum, which is commonly known as XP, is an inherited condition characterized by an extreme sensitivity to ultraviolet (UV) rays from sunlight. This condition mostly affects the eyes and areas of skin exposed to the sun. Some affected individuals also have problems involving the nervous system. The signs of xeroderma pigmentosum usually appear in infancy or early childhood. Many affected children develop a severe sunburn after spending just a few minutes in the sun. The sunburn causes redness and blistering that can last for weeks. Other affected children do not get sunburned with minimal sun exposure, but instead tan normally. By age 2, almost all children with xeroderma pigmentosum develop freckling of the skin in sun-exposed areas (such as the face, arms, and lips); this type of freckling rarely occurs in young children without the disorder. In affected individuals, exposure to sunlight often causes dry skin (xeroderma) and changes in skin coloring (pigmentation). This combination of features gives the condition its name, xeroderma pigmentosum. People with xeroderma pigmentosum have a greatly increased risk of developing skin cancer. Without sun protection, about half of children with this condition develop their first skin cancer by age 10. Most people with xeroderma pigmentosum develop multiple skin cancers during their lifetime. These cancers occur most often on the face, lips, and eyelids. Cancer can also develop on the scalp, in the eyes, and on the tip of the tongue. Studies suggest that people with xeroderma pigmentosum may also have an increased risk of other types of cancer, including brain tumors.
    [Show full text]
  • Trichothiodystrophy
    Trichothiodystrophy Author: Doctor Alfredo Rossi1 and Doctor C. Cantisani. Creation date: June 2004 Scientific Editor: Prof Antonella Tosti 1Dipartimento di Malattie Cutanee-Veneree Chirurgia Plastica-Ricostruttiva, Università degli studi di Roma “La Sapienza” Abstract Keywords Definition Epidemiology Etiology Clinical description Diagnostic methods Prenatal diagnosis Management References Abstract Trichothiodystrophy (TTD) is a rare autosomal recessive genetic disorder characterized by abnormal synthesis of the sulphur containing keratins and consequently hair dysplasia, associated with numerous symptoms affecting mainly organs derived from the neuroectoderm. This phenotypic aspect is due to mutations in the DNA-dependent ATPase/helicase subunit of TFIIH, XPB and XPD. Abnormalities in excision repair of ultraviolet (UV)-damaged DNA are recognized in about half of the patients. The clinical appearance is characterized by brittle and fragile hair, congenital ichthyosis, nail and dental dysplasias, cataract, progeria-like face, growth and mental retardation. The abnormalities are usually obvious at birth, with variable clinical expression. The variants of TTD, depending on their different associations, are known by the initials BIDS, IBIDS, PIBIDS, SIBIDS, ONMRS, as well as the eponyms of the Pollit, Tay, Sabinas syndromes or Amish brittle hair. The exact prevalence of TTD is unknown, but appears to be rather uncommon. About 20 cases of PIBI(D)S have been reported in the literature. Up to 1991, clinical data of 15 cases with IBIDS were published. Prenatal diagnostic of TTD is available. There is no specific treatment. Keywords Brittle hair, photosensitivity, ichthyosis, BIDS, IBIDS, PIBIDS, SIBIDS, ONMRS, Tay-syndrome Definition tail pattern). They named it Trichothiodystrophy, Trichothiodystrophy (TTD) is a group of rare noticing also an increased Photosensitivity and autosomal recessive disorders with heterogenic Ichthyosis in these patients (PIBIDS).
    [Show full text]
  • Proceedings of the 16Th Annual Meeting of the Society for Pediatric Dermatoiogy
    SPECIAL ARTICLE Pediatric Dermatology Vol. 9 No. 1 66-76 Proceedings of the 16th Annual Meeting of the Society for Pediatric Dermatoiogy WiUiamsburg, Virginia June 3a-July 3, 1991 Eleanor £. Sahn, M.D. Medical University of South Carolina Charleston, South Carolina A. Howiand Hartley, M.D. Children's Hospital National Medical Center Washington, D.C. Stephen Gellis, M.D. Children's Hospital Medical Center Boston, Massachusetts James E. Rasmussen, M.D. University of Michigan Medical Center Ann Arbor, Michigan Monday, July 1, 1991 ture by the newspaper account he received, dated December 17, 1799, telling of General George Dr. Alfred T. Lane (Stanford University) orga- Washington's death. We learn the story of General nized the sixteenth annual meeting of the Society Washington's rapid demise, probably from bacterial for Pediatric Dermatology, held in Wiliiamsburg, infection, hastened by the medical treatments of the Virgitiia. The seventh annual Sidney Hurwitz Lec- day, including frequent and copious blood letting. ture was delivered by Dr. Rona M. MacKie (Uni- There was a current saying, "more people died an- versity of Glasgow) on "Melanoma: Risk Factors in nually from lancets than from swords." Dysplastic Nevus Syndrome." President Anne Lucky (Cincinnati, Ohio) welcomed the society MELANOMA: RISK FACTORS AND members to Wiliiamsburg and introduced the first DYSPLASTIC NEVUS SYNDROME speaker. Dr. Rona MacKie first discussed risk factors in mel- anoma, citing several large case control studies car- COLONIAL MEDICINE ried out in western Canada, Scotland, Scandinavia, Dr. Tor A. Shwayder (Henry Ford Hospital) pre- and Germany. The frequency of melanoma has dou- sented a delightful and professional "Character In- bled each decade in Scandinavia, the United King- terpreter Portrayal of Iseiac Shwayder, Medical dom, and Germany.
    [Show full text]
  • Predisposition to Hematologic Malignancies in Patients With
    LETTERS TO THE EDITOR carcinomas but no internal cancer by the age of 29 years Predisposition to hematologic malignancies in and 9 years, respectively. patients with xeroderma pigmentosum Case XP540BE . This patient had a highly unusual pres - entation of MPAL. She was diagnosed with XP at the age Germline predisposition is a contributing etiology of of 18 months with numerous lentigines on sun-exposed hematologic malignancies, especially in children and skin, when her family emigrated from Morocco to the young adults. Germline predisposition in myeloid neo - USA. The homozygous North African XPC founder muta - plasms was added to the World Health Organization tion was present. 10 She had her first skin cancer at the age 1 2016 classification, and current management recommen - of 8 years, and subsequently developed more than 40 cuta - dations emphasize the importance of screening appropri - neous basal and squamous cell carcinomas, one melanoma 2 ate patients. Rare syndromes of DNA repair defects can in situ , and one ocular surface squamous neoplasm. She 3 lead to myeloid and/or lymphoid neoplasms. Here, we was diagnosed with a multinodular goiter at the age of 9 describe our experience with hematologic neoplasms in years eight months, with several complex nodules leading the defective DNA repair syndrome, xeroderma pigmen - to removal of her thyroid gland. Histopathology showed tosum (XP), including myelodysplastic syndrome (MDS), multinodular adenomatous/papillary hyperplasia. At the secondary acute myeloid leukemia (AML), high-grade age of 19 years, she presented with night sweats, fatigue, lymphoma, and an extremely unusual presentation of and lymphadenopathy. Laboratory studies revealed pancy - mixed phenotype acute leukemia (MPAL) with B, T and topenia with hemoglobin 6.8 g/dL, platelet count myeloid blasts.
    [Show full text]
  • Hereditary Hearing Impairment with Cutaneous Abnormalities
    G C A T T A C G G C A T genes Review Hereditary Hearing Impairment with Cutaneous Abnormalities Tung-Lin Lee 1 , Pei-Hsuan Lin 2,3, Pei-Lung Chen 3,4,5,6 , Jin-Bon Hong 4,7,* and Chen-Chi Wu 2,3,5,8,* 1 Department of Medical Education, National Taiwan University Hospital, Taipei City 100, Taiwan; [email protected] 2 Department of Otolaryngology, National Taiwan University Hospital, Taipei 11556, Taiwan; [email protected] 3 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City 100, Taiwan; [email protected] 4 Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei City 100, Taiwan 5 Department of Medical Genetics, National Taiwan University Hospital, Taipei 10041, Taiwan 6 Department of Internal Medicine, National Taiwan University Hospital, Taipei 10041, Taiwan 7 Department of Dermatology, National Taiwan University Hospital, Taipei City 100, Taiwan 8 Department of Medical Research, National Taiwan University Biomedical Park Hospital, Hsinchu City 300, Taiwan * Correspondence: [email protected] (J.-B.H.); [email protected] (C.-C.W.) Abstract: Syndromic hereditary hearing impairment (HHI) is a clinically and etiologically diverse condition that has a profound influence on affected individuals and their families. As cutaneous findings are more apparent than hearing-related symptoms to clinicians and, more importantly, to caregivers of affected infants and young individuals, establishing a correlation map of skin manifestations and their underlying genetic causes is key to early identification and diagnosis of syndromic HHI. In this article, we performed a comprehensive PubMed database search on syndromic HHI with cutaneous abnormalities, and reviewed a total of 260 relevant publications.
    [Show full text]
  • Goltz Syndrome) Head and Neck Surgery Manila Central University – Filemon D
    CASE REPORTS PHILI pp INE JOURNAL OF OTOLARYNGOLOGY -HEAD AND NECK SURGERY VOL . 32 NO. 2 JULY – DECEMBER 2017 John Emmanuel L. Ong, MD1 Unilateral Tonsilar Hypertrophy Emmanuel Tadeus S. Cruz, MD1,2 Clydine Maria Antonette G. Barrientos, MD1,3 in a 4-Year-Old Girl with Focal Dermal Hypoplasia 1 Department of Otorhinolaryngology (Goltz Syndrome) Head and Neck Surgery Manila Central University – Filemon D. Tanchoco Medical Foundation Hospital 2 Department of Otorhinolaryngology Head and Neck Surgery Quezon City General Hospital ABSTRACT 3 Department of Otorhinolaryngology Objective: To report a case of unilateral tonsillar hypertrophy resulting in severe Obstructive Sleep Head and Neck Surgery Makati Medical Center Apnea in a 4-year-old girl with focal dermal hypoplasia (FDH, Goltz or Goltz-Gorlin) Syndrome. Methods: Design: Case Report Setting: Tertiary Private Teaching Hospital Patient: One Correspondence: Dr. Emmanuel Tadeus S. Cruz Results: A 4-year-old girl with Goltz Syndrome (classical features of cutaneous and osteopathic Department of Otorhinolaryngology – Head and Neck Surgery Manila Central University – Filemon D. Tanchoco Medical disorders since birth) and unilateral tonsillar hypertrophy manifested with snoring and apneic Foundation Hospital Epifanio de los Santos Ave., Caloocan City 1400 episodes at two years of age. Polysomnography revealed severe Obstructive Sleep Apnea Philippines and Arterial Blood Gases revealed metabolic acidosis with hypoxemia. A tonsillectomy and Phone: (632) 367 2031 loc 1212 Email: [email protected]
    [Show full text]